ÍþÁ®Ï£¶ûwilliamhill¹Ù·½ÍøÕ¾

JP EN
ÍøÕ¾µØÍ¼
2023-12-13

ÍþÁ®Ï£¶ûwilliamhill¹Ù·½ÍøÕ¾ÖúÁ¦ÐÂ¼ÓÆÂÊ׸öÒßÃçÅäÒº¼°¹à×°Éú²úÉèÊ©Í깤

1.png


2.jpg

2023Äê11ÔÂ9ÈÕ£¬ÐÂ¼ÓÆÂÎÀÉú²¿³¤ÍõÒÒ¿µ³öϯÐÂ¼ÓÆÂÊ׸ö¶Ëµ½¶ËÍâµØÒßÃ翪·¢»ú¹¹ACES Manufacturing¿ªÒµÒÇʽ²¢Ö´Ç£¬ACES ManufacturingÓÉÃÀ¹úÖÆÒ©¾ÞͷĬɳ¶«ÓëÓ¢¹ú»Ý¿µÐÅÍлù½ðÅäºÏÓµÓеĺÏ×ÊÆóÒµHilleman LaboratoriesÔÚÐÂ¼ÓÆÂ½¨Éè¡£

On November 9, 2023, Singapore's Minister for Health Ong Ye Kung attended and delivered a speech at the opening of ACES Manufacturing, Singapore¡¯s first end-to-end local vaccine development facility in Singapore established by Hilleman Laboratories, which is an equal joint venture owned by the US pharmaceutical giant MSD and the Wellcome Trust of the United Kingdom.

3.png

4.jpg

ÍþÁ®Ï£¶ûwilliamhill¹Ù·½ÍøÕ¾¿Æ¼¼¼¯ÍÅÓÐÏÞ¹«Ë¾ºÜÐÒÔ˼ÓÈë¸ÃÏîÄ¿£¬²¢ÎªÐµÄACESÉèÊ©ÌṩÁËMiniKUFillÒ»Ì廯¹à×°¶³¹ØÁ¬Í³¡¢Ò»´ÎÐÔϵͳºÍÆäËûÏà¹Ø×°±¸£¬ÅäºÏ×ÊÖú¼ÓËÙÁËÉú²ú²¡¶¾ÒßÃçµÄÓÅÒìÉú²ú¹æ·¶£¨GMP£©ÉèÊ©µÄ½¨Éè£¬ÌØÊâÊÇÕë¶Ô°£²©À­ºÍÀ­É³ÈȵȵÍÊÕÈëºÍÖеÈÊÕÈë¹ú¼Ò£¨LMICs£©¼²²¡µÄÒßÃç¡£²¢Òòʵʱ½»»õºÍÏÖ³¡¸ßЧװÖöøÊܵ½¿Í»§µÄ¸ß¶ÈÆÀ¼Û¡£

Tofflon Science and Technology Group Co., Ltd. Was honored to participate in the project and provided the new ACES facility with the MiniKUFill integrated filling and lyophilization system, Single-Use Systems and other related equipment, which together helped accelerate the construction of the Good Manufacturing Practice (GMP) facility for the production of viral vaccines especially for diseases in low- and middle-income countries (LMICs) such as Ebola and Lassa Fever, and was highly lauded by the customer for timely delivery and efficient installation on site.


5.png

ÍþÁ®Ï£¶ûwilliamhill¹Ù·½ÍøÕ¾µÄMiniKUFillµÈ×°±¸Ê¹30,000ƽ·½Ã×µÄÑз¢ºÍÖÐÊÔÖÆÔ칤³§ÊµÏÖÁË´ÓÉÏÓÎÖÊÁÏÒ©Éú²úµ½ÏÂÓÎÖÆ¼Á²úÆ·µÄ¸ß¶ÈÎÞаµÄÄ £¿é»¯Éú²ú¡£Ëü¿ÉÒÔ˳ӦÔÚͳһÌõÉú²úÏßÉÏÉú²ú²î±ðµÄÒßÃçÆ½Ì¨¡£Í¬Ê±£¬¸Ãƽ̨»¹½«ÎªÐÂ¼ÓÆÂÍâµØÉú̬ϵͳÒÔ¼°ÖеÍÊÕÈë¹ú¼ÒµÄÑз¢ÊµÌå´´Á¢Åàѵʱ»ú¡£

ÍþÁ®Ï£¶ûwilliamhill¹Ù·½ÍøÕ¾½«Ò»Á¬Éî¸ûÉúÎïÖÆÒ©ÁìÓò£¬Æð¾¢Îªº£ÄÚÍâÉúÎïÖÆÒ©ÆóÒµ´øÀ´¸üºÃµÄ×°±¸ºÍºÄ²Ä£¬ÎªÐÐÒµµÄǰ½øºÍÉú³¤Ð¢Ë³Á¦Á¿¡£

Tofflon's MiniKUFill and other equipment have enabled the 30,000 square-meter R&D and pilot manufacturing plant to achieve highly flexible modular production from upstream drug substance production to downstream drug products. It can be adapted for the production of different vaccine platforms on the same production line. At the same time, the platform will also create training opportunities for the local Singapore ecosystem as well as R&D entities in LMICs.

Tofflon will continue to develop the field of biopharmaceuticals, strive to bring better equipment and consumables to biopharmaceutical companies at home and abroad, and contribute to the progress and development of the industry.




ÌìÏ·þÎñÈÈÏߣº 021-64906201(ÓªÏú) | 021-64905153(ÇåÁ®)
Copyright © 2020-2021ÍþÁ®Ï£¶ûwilliamhill¹Ù·½ÍøÕ¾ All Rights Reserved. »¦ICP±¸13216461ºÅ-1 ÍþÁ®Ï£¶ûwilliamhill¹Ù·½ÍøÕ¾
ÍøÕ¾µØÍ¼